SCHEMBL6183529

SCHEMBL6183529

CC(CCNC(=O)c1ccc(-n2cccc2)cc1)CC(=O)NCC#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
MCL1 Q07820 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
RAB9A P51151 3/20 0.45
LMNA P02545 1/20 0.45
AOC2 O75106 1/20 0.45
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 1/20 0.41
CTSB P07858 2/20 0.38
CTSL P07711 2/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183207 0.86 TDP1 (0.49) KMT2AMAPTTDP1
SCHEMBL6182428 0.83 CTSB (0.54) KMT2AHDAC3HDAC1CTSBCTSL
SCHEMBL6182799 0.82 LMNA (0.45) ALDH1A1MEN1KMT2AMAPTBLM
SCHEMBL7452326 0.82 SMN1; SMN2 (0.42) MEN1KMT2ARAB9ALMNASMN1; SMN2
SCHEMBL6183700 0.82 CTSL (0.53) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL7452250 0.81 HDAC1 (0.49) ALDH1A1KMT2ARAB9AHDAC3HDAC1
SCHEMBL7450457 0.81 MCHR1 (0.43) MEN1KMT2ARAB9ALMNAHDAC3
SCHEMBL7554411 0.80 EPHX2 (0.50) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL6182588 0.80 DRD2 (0.47) HDAC3HDAC1CTSBCTSLCTSS
SCHEMBL7453120 0.79 NAMPT (0.41) RAB9ASMN1; SMN2NPC1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1161415-B1 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2005-07-13 EP disclosed
US-6593327-B2 N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates AXYS PHARMACEUTICALS, INC. 2003-07-15 US disclosed
US-20030119788-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-06-26 US disclosed
US-6476026-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-11-05 US disclosed
US-20020086996-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2002-07-04 US disclosed
EP-1161415-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2000055126-A2 N-CYANOMETHYLAMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086996-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ALDH1A1 4049/4885MEN1 3977/4885KMT2A 2983/4885
US-20030119788-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ALDH1A1 4049/4885MEN1 3977/4885KMT2A 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.